
Public Consultation Summary Report

Clinical Practice Guidelines for Management of Sarcoma
– Series 2



June 2023

Scope of the Public Consultation report

This report refers to the public consultation and the response of the guideline development working group for the development of Clinical Practice Guidelines for Management of Sarcoma (Series 2).

Table of Contents

<i>Public Consultation Period</i>	3
<i>Professional Bodies contacted</i>	3
<i>Draft Guidelines availability</i>	3
<i>Multidisciplinary working party</i>	4
<i>Summary of changes to guidelines resulting from public consultation</i>	4

Public Consultation Period

The draft Clinical Practice Guidelines for Management of Sarcoma (Series 12) was up for public consultation from 15th May 2023 to 15th June 2023.

The notification of the public consultation was sent via email to all ANZSA members, Facebook, Twitter announcements through ANZSA and emails to professional and consumer groups (as listed below).

Professional Bodies contacted

- Royal Australia and New Zealand College of Radiologists (RANZCR)
- Medical Oncology Group of Australia (MOGA)
- Royal Australasian College of Surgeons (RACS)
- Australia Orthopaedic Association (AOA)
- Clinical Oncology Society of Australia (COSA)
- Royal Australian College of General Practitioners (RACGP)
- The Royal College of Pathologists of Australasia
- Australia and New Zealand Children Haematology Oncology Group (ANZCHOG)
- New Zealand Society for Oncology
- New Zealand Cancer Society
- Sarcoma Foundation New Zealand (Consumer organisation)
- Sock it to Sarcoma (Consumer organisation)
- Rainbows for Kate (Consumer organisation)
- Rare Cancers Consumer Group (Consumer organisation)
- Cooper Rice-Brading Foundation (Consumer organisation)

Draft Guidelines availability

The Draft Guidelines Was available on the ANZSA website 15th May-15th June

<https://sarcoma.org.au/pages/sarcoma-guidelines-draft> and included the following sections:

- Plain English Summary
- Topic 2 Q1 - What is the role of radiation therapy in the management of primary retroperitoneal sarcomas?
- Topic 2 Q2 - Does multi-visceral resection improve outcomes for patients with primary retroperitoneal sarcoma outcomes?
- Topic 2 Q3 - Role of Biopsy in retroperitoneal sarcoma? Safety, accuracy?
- Topic 2 Q4 - Role of chemotherapy in primary retroperitoneal sarcoma according to histologic subtype
- Topic 3 Q4 - Does the addition of high-dose chemotherapy have an impact on outcome of Ewing sarcoma and rhabdomyosarcoma compared to standard chemotherapy alone? in first line (a)? In relapse (b)?
- Administration Report
- Technical Report

Multidisciplinary working party

All comments were considered by the chair and members of the topic working party. Changes were made to the draft guidelines when it was considered as appropriate. A public consultation summary listing each comment that resulted in a change to the guidelines, or that the comment was considered but did not result in a change, and the reasons why it did not will be kept.

Summary of changes to guidelines resulting from public consultation

Feedback from consumers resulted in changes to the plain language section to aid in consumer understanding of the guidelines.

Feedback from New Zealand members resulted in a further language (Maori) to be added to the plain language section.